Search PubMed⌕ Search

Biomedical subjects

W Fiedler

Publications and source records attributed to W Fiedler.

105 records · Page 6Linked to original sources
PubMed1982

Differentiation and virus expression in BALB/Mo mice: endogenous Moloney leukemia virus is not activated in hematopoietic cells.

The endogenous Moloney leukemia virus (M-MuLV) in the BALB/Mo substrain of mice is activated during the first week after birth. Virus replication occurs in cells of the lymphatic system. Lymphoid cells therefore represent the target cells for virus replication and leukemic transformation. To investigate whether virus activation occurs during lymphoid cell differentiation, hematopoietic stem cells carrying the endogenous Mov-1 genome were transplanted to sublethally irradiated BALB/c mice. Effective colonization of the recipients was demonstrated by Southern DNA hybridization. No activation of the endogenous Mov-1 genome occurred during a 4-month observation period after the transplantation. Thus the first step in development of disease in BALB/Mo mice involves activation of the Mov-1 locus in a nonhematopoietic cell followed by superinfection of lymphatic cells and subsequent virus replication and virus spread.

Animals↗
PubMed1980

[On the synthesis of compounds with beta-adrenergic activity (author's transl)].

It is reported of the synthesis of 1-phenoxy-2-hydroxy-3-aminopropane derivatives with different substituents in the phenoxy residue as well as in the amino group. The potency and the efficacy of these derivatives depend on the substituents. By the introduction of the arylamino-ethyl residue into the nitrogen atom, beta-adrenergic locking agents with marked agonistic activity are obtained.

Adrenergic beta-Agonists↗
PubMed1979

A case of trisomy 22 in Pongo pygmaeus.

A behaviorally and clinically abnormal female orangutan was analyzed cytologically using general banding techniques and by an alkaline silver method for staining nucleolus organizer regions. The karyotype had 49 chromosomes, including an extra chromosome 22 (49,XX + 22). No variant chromosome types or heterozygous structural rearrangements were found. Nine of the 14 large acrocentric chromosomes, Nos. 11--17, and three of the five presumptive human G-group equivalents, i.e., two of three chromosomes 22, and one chromosome from pair 23, exhibited positive silver staining of the nucleolus organizer region (NOR).

Animals↗
PubMed1979

Demonstration of specific heterochromatic segments in the orangutan (Pongo pygmaeus) by a distamycin/DAPI double staining technique.

Orangutan metaphase chromosomes, obtained from a female animal with trisomy 22, were stained by a recently developed distamycin/DAPI fluorescent technique which had been shown to differentiate specific C-bands on human chromosomes, as well as by other banding techniques. Distamycin/DAPI-brilliant fluorescence was observed in the short arm regions of acrocentric chromosomes 11--17, 22 and 23, and a brightly fluorescent paracentromeric band was seen on chromosome 8. A smaller amount of fluorescence was found adjacent to the centromere of most of the other chromosomes. Sequential distamycin/DAPI and Giemsa C-staining of the metaphases revealed that the "hot-spots" on acrocentrics correspond to C-band material in their short arm. The less intensely fluorescent centric bands on other chromosomes coincide with centromeric C-bands. Reverse fluorescent staining of organutan chromosomes with chromomycin A3 revealed brightly fluorescent regions at short arms of some acrocentrics probably confined to the satellite, either in a heteromorphic form (Nos. 11, 14, 17) or of similar size (No. 22).

Animals↗
PubMedDate not supplied

Molecular characterization of surface topology in protein tertiary structures by amino-acylation and mass spectrometric peptide mapping.

Amino-acetylation and -succinylation reactions in combination with mass spectrometric peptide mapping of tryptic peptide mixtures have been employed for surface topology-probing of lysine residues in bovine ribonuclease A, lysozyme, and horse heart myoglobin as model proteins of different surface structures. Direct molecular weight determinations identifying the precise number of acyl groups in partially modified proteins were obtained by electrospray and 252Cf-plasma desorption mass spectrometry. Electrospray mass spectra of multiply protonated molecular ions and deuterium exchange experiments provided a relative conformational characterization of protein derivatives and enabled the direct determinations of intact, partially acylated heme-myoglobin derivatives. Tryptic peptide mapping analysis, using plasma desorption and fast atom bombardment mass spectrometry, ascertained by mass spectrometric characterization of HPLC-separated modified peptides, yielded the exact identification of acylation sites. Relative reactivities of the amino acylation were derived from the peptide mapping data and from quantitative estimations of modified peptides upon acetylation/trideuteroacetylation and provided direct correlations with the relative surface accessibilities of lysine-epsilon-amino groups taken from X-ray crystallographic structure data of the proteins. The reactive lysine-41 residue in ribonuclease A which is part of the substrate binding site was directly identified from the mass spectrometric data. These results indicate tertiary structure-selective acylation combined with mass spectrometric peptide mapping as an efficient approach for the molecular characterization of surface topology and reactive fundamental lysine residues in proteins.

Acylation↗
PubMedDate not supplied

Molecular characterization of a conformational epitope of hen egg white lysozyme by differential chemical modification of immune complexes and mass spectrometric peptide mapping.

A new approach for the characterization of conformationally dependent epitope structures in protein antigens is described using differential chemical modification of immune complexes in combination with mass spectrometric peptide mapping analysis. Well-established methods for epitope characterization are frequently not applicable to conformationally dependent epitopes, and direct methods of structure analysis such as X-ray crystallography of immune complexes have been successful only in a few cases. Our approach combines tertiary structure-selective chemical modification of immune complexes with the molecular characterization of reaction products by mass spectrometric peptide mapping. The comparison of the modification pattern of free and antibody-bound antigen provides the identification of residues protected from modification by the antibody. These residues hence are characterized as part of the epitope structure. The well-characterized hen egg white lysozyme and a corresponding monoclonal IgM-type antibody were investigated as a model system. Specific modification reactions for arginine, lysine, and tyrosine residues were performed, and the modification sites in free and antibody-bound antigen were determined by mass spectrometric peptide mapping. The R14 residue and residues K13 and K96 in the antibody-bound lysozyme were found to be protected from modification, comprising a surface of spatially adjacent residues by folding of the native protein. In contrast, other K and R residues as well as Y20 and Y23 showed no significant shielding from modification in the immune complex. These results provided an estimation of the molecular epitope surface area of native lysozyme.

Animals↗
PubMedDate not supplied

A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer.

Immunological effector mechanisms of monoclonal antibodies such as antibody-dependent cytotoxicity can be augmented by the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2 (IL-2). Therefore twelve patients with metastatic colorectal cancer were treated with 300 microg GM-CSF and 6 million units IL-2 subcutaneously daily from day 1 to 10 followed by a three week rest period. Of the edrecolomab 400 mg was given on day 3 of the first cycle. The dose was reduced to 150 mg on subsequent cycles. A maximum of four cycles was administered. Toxicity was manageable on an outpatient basis. No partial or complete responses were observed in these 12 patients. Median time to treatment failure was 67 days and median survival 287 days. Immunological parameters were monitored throughout the study.

Aged↗
PubMedDate not supplied

Role of angiogenesis inhibitors in acute myeloid leukemia.

Neovascularization is increasingly recognized as an important factor in the pathogenesis of hematologic malignancies as well as solid tumors. The complex interactions between several cell types and numerous cytokine mediators suggest the involvement of autocrine and paracrine signaling mechanisms. Vascular endothelial growth factor (VEGF) in particular is critical to both stimulation of leukemic growth and proliferation of endothelial cells. Tyrosine kinase receptors specific for certain growth factors represent attractive target molecules for anticancer therapy. SU5416 is a competitive inhibitor of VEGF receptor subtypes VEGFR-1 and VEGFR-2 and stem cell factor receptor c-kit. Preclinical evidence shows that SU5416 effectively inhibits VEGF-induced endothelial cell proliferation and slows growth of subcutaneous solid tumor xenografts. This agent is in late-stage clinical trials in patients with solid tumors, and a Phase 2 study was recently initiated to evaluate its utility in the treatment of acute myeloid leukemia. In this Phase 2 study, investigators are seeking to determine the response rate to the antiangiogenic agent SU5416. Translational research in this study is intended to aid our understanding of the precise mechanisms by which SU5416 affects acute myeloid leukemia cells and the bone marrow microenvironment.

Acute Disease↗